Analysts Set TG Therapeutics, Inc. (NASDAQ:TGTX) Target Price at $22.25

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have received an average rating of “Moderate Buy” from the eight research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $22.25.

TGTX has been the topic of several analyst reports. The Goldman Sachs Group raised shares of TG Therapeutics from a “sell” rating to a “neutral” rating and dropped their price target for the stock from $16.00 to $12.00 in a research report on Wednesday, August 2nd. StockNews.com lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. HC Wainwright reaffirmed a “buy” rating and set a $41.00 price target on shares of TG Therapeutics in a research report on Monday, September 18th. Jefferies Financial Group reaffirmed a “buy” rating and set a $23.00 price target on shares of TG Therapeutics in a research report on Wednesday, November 1st. Finally, B. Riley dropped their price objective on shares of TG Therapeutics from $32.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, October 20th.

Institutional Investors Weigh In On TG Therapeutics

Large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp grew its stake in TG Therapeutics by 25.7% during the second quarter. Bank of New York Mellon Corp now owns 589,639 shares of the biopharmaceutical company’s stock worth $14,647,000 after buying an additional 120,406 shares in the last quarter. Tradition Wealth Management LLC boosted its stake in shares of TG Therapeutics by 27.6% in the 1st quarter. Tradition Wealth Management LLC now owns 8,243 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 1,785 shares in the last quarter. Level Four Advisory Services LLC acquired a new stake in shares of TG Therapeutics in the 1st quarter valued at approximately $341,000. Handelsbanken Fonder AB boosted its stake in shares of TG Therapeutics by 81.3% in the 2nd quarter. Handelsbanken Fonder AB now owns 22,300 shares of the biopharmaceutical company’s stock valued at $554,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Quantum Private Wealth LLC boosted its stake in shares of TG Therapeutics by 47.8% in the 2nd quarter. Quantum Private Wealth LLC now owns 62,228 shares of the biopharmaceutical company’s stock valued at $1,546,000 after purchasing an additional 20,132 shares in the last quarter. 57.92% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $12.82 on Thursday. The company’s fifty day simple moving average is $8.87 and its 200-day simple moving average is $16.60. The company has a quick ratio of 4.95, a current ratio of 5.53 and a debt-to-equity ratio of 0.60. The firm has a market cap of $1.94 billion, a PE ratio of -45.79 and a beta of 2.10. TG Therapeutics has a 12 month low of $6.46 and a 12 month high of $35.67.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.29 by $0.44. TG Therapeutics had a negative net margin of 13.65% and a negative return on equity of 35.58%. The business had revenue of $165.80 million for the quarter, compared to analyst estimates of $23.91 million. During the same quarter in the previous year, the firm posted ($0.26) earnings per share. The firm’s revenue for the quarter was up 17538.3% on a year-over-year basis. Equities research analysts expect that TG Therapeutics will post 0.02 EPS for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.